Dr. Reddy’s Biosimilar Products

Dr. Reddy's Biologics is committed to providing affordable and innovative Biosimilars that are within reach. Over and above the six biosimilars launched in the market, Biologics has a growing portfolio of molecules primarily in the space of Oncology & auto-immune disorders. Every step we take is rooted in our unwavering commitment to improving lives globally.

Biosimilars

A biologic, or biopharmaceutical, is a medicinal product derived from living organisms (plants, animals, or microorganisms), often created using recombinant DNA technology. A biosimilar is a biologic that closely resembles an already authorised reference biologic, with no significant differences in quality, safety, or efficacy. Our biosimilar products are developed with the Totality of Evidence approach, as defined by FDA, WHO, and other regulatory bodies.

Successful Regulatory Audits

Capacity of Production

Expert Scientists

sq. Meters Facility area

Our Products

7 Commercially Approved Products .

Reditux

Reditux, our Biosimilar version of Rituximab—marks a milestone achievement

Grafeel

Chemotherapy Induced-Neutropenia, Neutropenia

Cresp

Chronic Kidney Disease

Hervycta

HER2-Positive early breast cancer

Peg-grafeel

Chemotherapy Induced Neutropenia

Versavo

Metastatic colorectal cancer , Metastatic breast cancer

Womab

Dr. Reddy’s Biologics launched Womab (pertuzumab), its latest biosimilar in India. Womab is a biosimilar to Roche’s Perjeta® and is indicated for the treatment of HER2-positive breast cancer. This launch further expands Dr. Reddy’s Biologics’ commitment t

Connect with us

Are you a patient or a caregiver? Or a medical professional or a partner looking for these life-saving treatments?

Let's Connect

Our Pipeline

Within the areas of oncology, auto-immune disorders, osteoporosis and ALS, Dr. Reddy’s Biologics team is working on developing over ten products, including novel molecules. The future is coming, and it is hopeful.

*In-licensed

Denosumab*

Oncology, Osteoporosis

Monoclonal Antibody

Abatacept

Auto- immune, Rheumatoid arthritis

Fc Fusion Protein

Daratumumab*

Oncology

Monoclonal Antibody

Check Pipeline

We Meet Global Standards

Our Expertise in Biologics

Dr. Reddy's Biologics is dedicated to making advanced medicines accessible worldwide. Our experienced team, coupled with world-class infrastructure, enables us to create effective biosimilars that reduce the cost burden on patients and payers. As a leader in the fast-growing biosimilar sector, Dr.Reddy's Biologics markets six biosimilars across multiple countries and has a robust pipeline in development.

Explore Biologics